Substantial EFS improvement with selpercatinib in RET fusion-positive disease ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

In the first phase 3 trial of a RET inhibitor as adjuvant therapy, selpercatinib markedly improved event-free survival vs placebo in early-stage RET fusion-positive NSCLC.

The two main categories for lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Large cell lung cancer (LCLC) is a type of NSCLC. While the conditions share some ...

Multidisciplinary evaluation, including thoracic surgical consultation, is crucial for oligometastatic NSCLC patients to optimize treatment strategies. Lung surgery for oligometastatic NSCLC shows ...

For patients with locally advanced non–small cell lung cancer (NSCLC), multidisciplinary team input optimizes outcomes by tailoring patient care, which is especially important during this era of ...

Surgery is a common treatment for non-small cell lung cancer (NSCLC), particularly when the disease is detected early and the tumor is small and is only in one part of the lung. For small cell lung ...

A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer ...

Individuals with chronic obstructive pulmonary disease (COPD) are already compromised, so the prospect of removing all or part of a lung is especially daunting for these patients if they are also ...

At age 31, Seattle architect Amal Moussa was diagnosed with a rare stage 3 lung tumor after experiencing sudden breathing ...